Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma

World Journal of Hepatology

Volumn 6, Issue 9, 2014, Pages 670-676

  Shomura, Masako ^a   Kagawa, Tatehiro ^b   Shiraishi, Koichi ^b   Hirose, Shunji ^b   Arase, Yoshitaka ^b   Koizumi, Jun ^b   Mine, Tetsuya ^b  

^a TOKAI UNIVERSITY   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Drug toxicity; Hepatocellular carcinoma; Molecular targeted therapy; Nursing intervention; Surrogate marker

Indexed keywords

EID: 84911954110     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v6.i9.670     Document Type: Article

References (37)

1. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008; 14: 4300-4308 [PMID: 18666317 DOI: 10.3748/wjg.14.4300]
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]
3. Ochiai T, Ikoma H, Okamoto K, Kokuba Y, Sonoyama T, Otsuji E. Clinicopathologic features and risk factors for extrahepatic recurrences of hepatocellular carcinoma after curative resection. World J Surg 2012; 36: 136-143 [PMID: 22051887 DOI: 10.1007/s00268-011-1317-y]
4. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022 [PMID: 21374666 DOI: 10.1002/hep.24199]
5. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011; 29: 339-364 [PMID: 21829027 DOI: 10.1159/000327577]
6. Kokudo N, Nakajima J, Hatano E, Numata K. Current status of hepatocellular carcinoma treatment in Japan: practical use of sorafenib (Nexavar®). Clin Drug Investig 2012; 32 Suppl 2: 25-35 [PMID: 22873625 DOI: 10.2165/1163023-S0-000000000-00000]
7. European Association for Study of Liver; European Organisation for Research and Treatment of Cancer. EASLEORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer 2012; 48: 599-641 [PMID: 22424278 DOI: 10.1016/j.ejca.2011.12.021]
8. Verslype C, Rosmorduc O, Rougier P. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 Suppl 7: vii41-vii48 [PMID: 22997453 DOI: 10.1093/annonc/mds225]
9. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857]
10. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34 [PMID: 19095497 DOI: 10.1016/S1470-2045(08)70285-7]
11. Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Sakata K, Matsugaki S, Kajiwara M, Fukuizumi K, Tajiri N, Matsukuma N, Sakai T, Ono N, Yano Y, Koga H, Kurogi J, Takata A, Sumie S, Satani M, Yamada S, Niizeki T, Aino H, Iwamoto H, Torimura T, Sata M. Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma. Oncology 2013; 84: 108-114 [PMID: 23147476 DOI: 10.1159/000342650]
12. Zhang X, Yang XR, Huang XW, Wang WM, Shi RY, Xu Y, Wang Z, Qiu SJ, Fan J, Zhou J. Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review. Hepatobiliary Pancreat Dis Int 2012; 11: 458-466 [PMID: 23060390 DOI: 10.1016/S1499-3872(12)60209-4]
13. Estfan B, Byrne M, Kim R. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy. Am J Clin Oncol 2013; 36: 319-324 [PMID: 22547010 DOI: 10.1097/COC.0b013e3182468039]
14. Koschny R, Gotthardt D, Koehler C, Jaeger D, Stremmel W, Ganten TM. Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma. Oncology 2013; 84: 6-13 [PMID: 23075905 DOI: 10.1159/000342425]
15. Vincenzi B, Santini D, Russo A, Addeo R, Giuliani F, Montella L, Rizzo S, Venditti O, Frezza AM, Caraglia M, Colucci G, Del Prete S, Tonini G. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist 2010; 15: 85-92 [PMID: 20051477 DOI: 10.1634/theoncologist.2009-0143]
16. Otsuka T, Eguchi Y, Kawazoe S, Yanagita K, Ario K, Kitahara K, Kawasoe H, Kato H, Mizuta T. Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib. Hepatol Res 2012; 42: 879-886 [PMID: 22469363 DOI: 10.1111/j.1872-034X.2012.00991.x]
17. Senst BL, Achusim LE, Genest RP, Cosentino LA, Ford CC, Little JA, Raybon SJ, Bates DW. Practical approach to determining costs and frequency of adverse drug events in a health care network. Am J Health Syst Pharm 2001; 58: 1126-1132 [PMID: 11449856]
18. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 2002; 36: 1331-1336 [PMID: 12196047 DOI: 10.1345/aph.1A333]
19. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008; (2): CD000011 [PMID: 18425859 DOI: 10.1002/14651858.CD000011]
20. Decker V, Spoelstra S, Miezo E, Bremer R, You M, Given C, Given B. A pilot study of an automated voice response system and nursing intervention to monitor adherence to oral chemotherapy agents. Cancer Nurs 2009; 32: E20-E29 [PMID: 19816160 DOI: 10.1097/NCC.0b013e3181b31114]
21. Given BA, Spoelstra SL, Grant M. The challenges of oral agents as antineoplastic treatments. Semin Oncol Nurs 2011; 27: 93-103 [PMID: 21514479 DOI: 10.1016/j.soncn.2011.02.003]
22. Spoelstra SL, Given BA, Given CW, Grant M, Sikorskii A, You M, Decker V. An intervention to improve adherence and management of symptoms for patients prescribed oral chemotherapy agents: an exploratory study. Cancer Nurs 2013; 36: 18-28 [PMID: 23235499 DOI: 10.1097/NCC.0b013e3182551587]
23. Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg 2007; 245: 909-922 [PMID: 17522517 DOI: 10.1097/01.sla.0000254368.65878.da]
24. Hartigan K. Patient education: the cornerstone of successful oral chemotherapy treatment. Clin J Oncol Nurs 2003; 7: 21-24 [PMID: 14705496 DOI: 10.1188/03.CJON.S6.21-24]
25. Neuss MN, Polovich M, McNiff K, Esper P, Gilmore TR, LeFebvre KB, Schulmeister L, Jacobson JO. 2013 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards including standards for the safe administration and management of oral chemotherapy. Oncol Nurs Forum 2013; 40: 225-233 [PMID: 23619103 DOI: 10.1188/13.ONF.40-03AP2]
26. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60 [PMID: 20175033 DOI: 10.1055/s-0030-1247132]
27. Japan Clinical Oncology Group. Common Terminology Criteria for Adverse Events (CTCAE) v4.0-Japan Clinical Oncology Group. Available from: URL: http://www.jcog.jp/doctor/tool/ctcaev4.html, 2013 (accessed Jul 29, 2013)
28. Mizukami H, Kagawa T, Arase Y, Nakahara F, Tsuruya K, Anzai K, Hirose S, Shiraishi K, Shomura M, Koizumi J, Tobita K, Mine T. Complete response after short-term sorafenib treatment in a patient with lymph node metastasis of hepatocellular carcinoma. Case Rep Oncol 2012; 5: 380-384 [PMID: 23525021 DOI: 10.1159/000341259]
29. Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, Ladrón de Guevara L, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Cihon F, Heldner S, Marrero JA. First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) noninterventional study. Int J Clin Pract 2012; 66: 675-683 [PMID: 22698419 DOI: 10.1111/j.1742-1241.2012.02940.x]
30. Iavarone M, Cabibbo G, Piscaglia F, Zavaglia C, Grieco A, Villa E, Cammà C, Colombo M. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 2011; 54: 2055-2063 [PMID: 21898496 DOI: 10.1002/hep.24644]
31. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008; 7: 3129-3140 [PMID: 18852116 DOI: 10.1158/1535-7163.MCT-08-0013]
32. Lee JH, Chung YH, Kim JA, Shim JH, Lee D, Lee HC, Shin ES, Yoon JH, Kim BI, Bae SH, Koh KC, Park NH. Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma. Cancer 2013; 119: 136-142 [PMID: 22736425 DOI: 10.1002/cncr.27705]
33. Jain L, Sissung TM, Danesi R, Kohn EC, Dahut WL, Kummar S, Venzon D, Liewehr D, English BC, Baum CE, Yarchoan R, Giaccone G, Venitz J, Price DK, Figg WD. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res 2010; 29: 95 [PMID: 20630084 DOI: 10.1186/1756-9966-29-95]
34. Morimoto M, Numata K, Moriya S, Kondo M, Nozaki A, Morioka Y, Maeda S, Tanaka K. Inflammation-based prognostic score for hepatocellular carcinoma patients on sorafenib treatment. Anticancer Res 2012; 32: 619-623 [PMID: 22287754]
35. Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, Xu F, Yassine M. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28: 1351-1357 [PMID: 20142600 DOI: 10.1200/JCO.2008.21.7828]
36. Balagula Y, Garbe C, Myskowski PL, Hauschild A, Rapoport BL, Boers-Doets CB, Lacouture ME. Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. Int J Dermatol 2011; 50: 129-146 [PMID: 21244375 DOI: 10.1111/j.1365-4632.2010.04791.x]
37. Craven O, Hughes CA, Burton A, Saunders MP, Molassiotis A. Is a nurse-led telephone intervention a viable alternative to nurse-led home care and standard care for patients receiving oral capecitabine? Results from a large prospective audit in patients with colorectal cancer. Eur J Cancer Care (Engl) 2013; 22: 413-419 [PMID: 23527965 DOI: 10.1111/ecc.12047]